Paclitaxel in combination with carboplatin as salvage treatment in patients with castration-resistant prostate cancer: a Hellenic oncology research group multicenter phase II study
被引:25
作者:
Kentepozidis, N.
论文数: 0引用数: 0
h-index: 0
机构:
251 AF Hosp, Dept Med Oncol, Athens 11525, Greece251 AF Hosp, Dept Med Oncol, Athens 11525, Greece
Kentepozidis, N.
[1
]
Soultati, A.
论文数: 0引用数: 0
h-index: 0
机构:
251 AF Hosp, Dept Med Oncol, Athens 11525, Greece251 AF Hosp, Dept Med Oncol, Athens 11525, Greece
Soultati, A.
[1
]
Giassas, S.
论文数: 0引用数: 0
h-index: 0
机构:
IASO Gen Hosp, Dept Med Oncol, Athens, Greece251 AF Hosp, Dept Med Oncol, Athens 11525, Greece
Giassas, S.
[2
]
Vardakis, N.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Gen Hosp Heraklion, Dept Med Oncol, Iraklion, Greece251 AF Hosp, Dept Med Oncol, Athens 11525, Greece
Vardakis, N.
[3
]
Kalykaki, A.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Gen Hosp Heraklion, Dept Med Oncol, Iraklion, Greece251 AF Hosp, Dept Med Oncol, Athens 11525, Greece
Kalykaki, A.
[3
]
Kotsakis, A.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Gen Hosp Heraklion, Dept Med Oncol, Iraklion, Greece251 AF Hosp, Dept Med Oncol, Athens 11525, Greece
Kotsakis, A.
[3
]
Papadimitraki, E.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Gen Hosp Heraklion, Dept Med Oncol, Iraklion, Greece251 AF Hosp, Dept Med Oncol, Athens 11525, Greece
Papadimitraki, E.
[3
]
Pantazopoulos, N.
论文数: 0引用数: 0
h-index: 0
机构:
IASO Gen Hosp, Dept Med Oncol, Athens, Greece251 AF Hosp, Dept Med Oncol, Athens 11525, Greece
Pantazopoulos, N.
[2
]
Bozionellou, V.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Gen Hosp Heraklion, Dept Med Oncol, Iraklion, Greece251 AF Hosp, Dept Med Oncol, Athens 11525, Greece
Bozionellou, V.
[3
]
Georgoulias, V.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Gen Hosp Heraklion, Dept Med Oncol, Iraklion, Greece251 AF Hosp, Dept Med Oncol, Athens 11525, Greece
Georgoulias, V.
[3
]
机构:
[1] 251 AF Hosp, Dept Med Oncol, Athens 11525, Greece
[2] IASO Gen Hosp, Dept Med Oncol, Athens, Greece
[3] Univ Gen Hosp Heraklion, Dept Med Oncol, Iraklion, Greece
Introduction To evaluate the efficacy and tolerance of biweekly paclitaxel and carboplatin combination in patients with castration-resistant prostate cancer. Patients and methods Patients were treated with paclitaxel at the dose of 135 mg/m(2) followed by carboplatin AUC 3 on day 1 every 2 weeks in cycles of 28 days. Results Thirty-eight patients with castration-resistant prostate cancer were enrolled, and all of them had received frontline chemotherapy with docetaxel and prednisone, while 24 (63.2 %) had received 2 or more prior chemotherapy regimens. In an intention-to-treatment analysis, a clinical and/or biochemical response (>50 % decline) was observed in 10 patients (26.3 %; 95 % CI, 12.3-40.3 %), stable disease in 13 (34.2 %) and progressive disease in 15 (39.5 %). The median duration of response was 6.1 months (range, 1.0-9.8), the median time to tumor progression (TTP) 3.6 months (95 % CI, 2.1-5.2) and the median overall survival 9.9 months (95 % CI, 6.2-13.6). The probability for 1-year survival was 43 %. Grade 3 and 4 neutropenia was observed in three (7.9 %) and nine (23.7 %) patients, respectively. Conclusion The biweekly administration of paclitaxel/carboplatin regimen in patients with castration-resistant prostate cancer is an active and well-tolerated regimen which merits to be further evaluated in the context of salvage treatment.